Rational use of tocilizumab in COVID-19.Ann Rheum Dis. 2020 Jul 31 [Online ahead of print]AR
Jain, Siddharth, and Shefali Khanna Sharma. "Rational Use of Tocilizumab in COVID-19." Annals of the Rheumatic Diseases, 2020.
Jain S, Sharma SK. Rational use of tocilizumab in COVID-19. Ann Rheum Dis. 2020.
Jain, S., & Sharma, S. K. (2020). Rational use of tocilizumab in COVID-19. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2020-218519
Jain S, Sharma SK. Rational Use of Tocilizumab in COVID-19. Ann Rheum Dis. 2020 Jul 31; PubMed PMID: 32737106.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rational use of tocilizumab in COVID-19. AU - Jain,Siddharth, AU - Sharma,Shefali Khanna, Y1 - 2020/07/31/ PY - 2020/07/04/received PY - 2020/07/11/revised PY - 2020/07/15/accepted PY - 2020/8/2/entrez KW - antirheumatic agents KW - biological therapy KW - communicable diseases, imported KW - cytokines KW - inflammation JF - Annals of the rheumatic diseases JO - Ann. Rheum. Dis. SN - 1468-2060 UR - https://www.unboundmedicine.com/medline/citation/32737106/Rational_use_of_tocilizumab_in_COVID-19 L2 - https://ard.bmj.com/lookup/pmidlookup?view=long&pmid=32737106 DB - PRIME DP - Unbound Medicine ER -